Thymoma Clinical Trials 2023

What are the top hospitals conducting thymoma research?

In the realm of clinical trials for thymoma, several hospitals have emerged as leaders in pushing the boundaries of medical research and treatment options. One such institution is the National Institutes of Health Clinical Center located in Bethesda, where scientists are currently conducting four active thymoma trials. Over time, they have made significant contributions with a total of five completed studies since initiating their first trial in 2011. Not too far away, Memorial Sloan Kettering Cancer Center in New york has also dedicated resources to thymoma research. With two ongoing trials and three all-time completed trials since 2009, this center continues to make strides towards better understanding and managing this rare condition.

Heading south to Houston's M D Anderson Cancer Center we find another hub for advancing knowledge about thymoma. The researchers at this prestigious facility are actively engaged in two clinical trials focused on exploring new treatment options for patients with thymoma. This dedication aligns with their track record of four previous studies carried out since recording their initial trial back in 2011.

Joining these top institutions is Moffitt Cancer Center situated in Tampa which embarks upon its journey into studying treatments related to thymona from relatively recent times starting only around2018 while engaging themselves on two ongoing investigations .

It's worth noting that within Bethesda itself lies another branch of the National Institutes of Health Clinical Center specifically known by its address "9000 Rockville Pike." Committed to enhancing our understanding and management of thymoma, they too conduct two active clinical trials while having successfully conducted eight previous t-studies Since tracing evidence only back until2007

Thymoma remains an enigmatic condition with limited treatment options; however, thanks to the relentless pursuits led by these remarkable hospitals nationwide, hope shines brightly for patients affected by this rare form of cancer. These centers serve as beacons of innovation and collaboration that bring us one step closer toward unraveling the mysteries surrounding thymoma, ultimately improving the lives of those impacted by this challenging disease.

Which are the best cities for thymoma clinical trials?

In the realm of thymoma clinical trials, several cities emerge as key players in research and development. Anchorage, Alaska leads the way with 8 active trials, investigating treatments like Ramucirumab. Houston, Texas follows closely behind with 6 ongoing studies exploring innovative approaches such as pembrolizumab treatment, robotic-assisted surgery, and magnetic resonance imaging. Bethesda, Maryland also boasts 6 active trials focusing on options like Avelumab and Sunitinib for thymomas categorized as F/Not Otherwise Specified (NOS). New york City contributes significantly to this field with 5 active trials examining various treatment modalities including robotic-assisted surgery and Cetuximab among others. Lastly, Tampa, Florida adds to the mix with 4 active trials emphasizing therapies like Ramucirumab and Pembrolizumab. These cities provide individuals facing thymoma access to cutting-edge clinical trials that contribute to advancements in care for better outcomes.

Which are the top treatments for thymoma being explored in clinical trials?

Thymoma, a rare form of cancer affecting the thymus gland, is currently being explored in various clinical trials to identify effective treatments. Among the top contenders are:

• Robotic-Assisted Surgery: This innovative approach has shown promise and is currently under investigation in one active trial for thymoma. Its first listing occurred in 2022.

• Home-based cardiac rehabilitation: Another intriguing option being explored through one active trial, home-based cardiac rehabilitation offers potential benefits for individuals with thymoma. It was first listed as a treatment option in 2021.

• Magnetic Resonance Imaging (MRI): Utilizing advanced imaging techniques, MRI has gained attention as a potential tool for diagnosing and monitoring thymoma patients. It entered the clinical trial landscape back in 2011 and continues to be studied.

• VMD-928 Tablets and Capsules: In an ongoing clinical trial, VMD-928 at both tablet (300 mg) and capsule (100 mg) strengths shows promise as a treatment option for thymoma patients. The initial listing took place in 2018.

• Pembrolizumab: With four all-time trials dedicated to studying its effectiveness against thymoma since its introduction in 2015, pembrolizumab holds great potential as an immunotherapy drug that could revolutionize treatment outcomes.

These exciting avenues of exploration offer hope to those impacted by this challenging disease while advancing our understanding and management of thymoma.

What are the most recent clinical trials for thymoma?

Recent clinical trials have brought forth promising advancements in the treatment of thymoma, providing renewed hope for patients. One notable trial involves the investigation of single-agent KFA115, which has shown potential benefits in early-phase studies. Additionally, PT-112 is being evaluated in a Phase 2 trial to assess its effectiveness against thymoma. Another study focuses on M7824 as a potential therapy option for this rare cancer type. Ramucirumab and Nivolumab have also been investigated in separate trials to determine their efficacy and safety profiles specifically for thymoma patients. With these ongoing research efforts, we anticipate improved outcomes and tailored treatment approaches for individuals battling thymoma.

What thymoma clinical trials were recently completed?

Recently completed clinical trials have made significant strides in the field of thymoma research. In December 2019, Nagla Abdel Karim sponsored a trial investigating the potential of Bosutinib as a treatment for this rare cancer. Another noteworthy trial was conducted by Xencor, Inc., which concluded in July 2018 and explored the efficacy of XmAb20717. These advancements highlight the dedication of researchers in their quest to improve treatments for thymoma patients and offer hope for those affected by this challenging disease.